Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Zixi, Yi"'
Publikováno v:
Chinese Medical Journal, Vol 135, Iss 9, Pp 1133-1134 (2022)
Externí odkaz:
https://doaj.org/article/517a0a5d14ec4013b252185b0683145f
Autor:
Zixi Yi, Zhongqiang Yao, Dan Xu, Chuanhui Xu, Wenqiang Fang, Zhanfei Guo, Yong Wang, Jianlin Huang, Qin Li, Hong Zhang, Anbin Huang, Lijun Wu, Zhenbiao Wu, Huifang Guo, Fengxiao Zhang, Jing Lu, Zhenchun Zhang, Zhongming Yu, Zhanyun Da, Li Luo, Bin Wu, Henglian Wu, Lin Zeng, Rong Mu
Publikováno v:
Vaccines, Vol 10, Iss 10, p 1604 (2022)
The coronavirus disease 2019 (COVID-19) pandemic has imposed enormous morbidity and mortality burdens. Patients with rheumatic diseases (RDs) are vulnerable to the COVID-19 infection, given their immunocompromised status. Ensuring acceptance of the C
Externí odkaz:
https://doaj.org/article/6e060e5cdf954755adc4acf1f8206f0f
Autor:
Dan, Xu, Lingling, Zhu, Ruyi, Cai, Zixi, Yi, Haishun, Zhang, Gang, Guo, Shuang, Liu, Jian, Xu, Qingwen, Wang, Yin, Su, Xinyi, Li, Jinxia, Zhao, Rong, Mu
Publikováno v:
Clinical and Experimental Rheumatology. 39:721-726
Scleroderma renal crisis (SRC) is a life-threatening syndrome. The early identification of patients at risk is essential for timely treatment to improve the outcome. Therefore, it is of great interest to provide a personalised tool to predict risk of
Autor:
Tiangang Zhu, Jingyi Ren, Tian Liu, Haihong Yao, Feng Zhang, Yuhui Li, Dan Xu, Zixi Yi, Xia Zhang, Chun Li, Xintong Jiang, Ruyi Cai, Rong Mu
Publikováno v:
Rheumatology (Oxford, England). 61(6)
Background Cardiac involvement is a major cause of death in SSc, while early detection remains a challenge. Objectives The purpose of this study was to investigate the prevalence and clinical implications of cardiac impairment in SSc. Methods Ninety-
Publikováno v:
Chinese Medical Journal. 135:1133-1134
Publikováno v:
Autoimmunity Reviews
Objectives The impact of rheumatic diseases on COVID-19 infection remains poorly investigated. Here we performed a systematic review and meta-analysis to evaluate the outcomes of COVID-19 in patients with rheumatic diseases. Methods We systematically